Hemo Organic Ltd (HEMORGANIC) is currently trading at 20.99 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Hemo Organic Limited is a small, publicly listed Indian company historically engaged in chemical manufacturing which shifted to trading activities (rice and textile) and is now transitioning back into specialty chemical production by commissioning a new plant to produce 2,6‑Dichloro Aniline and Para Chloro Meta Cresol near Khambhat, Gujarat, targeting pharmaceutical and leather industry customers. The audited FY2026 results show a clear financial stress point: total income materially declined to approximately Rs.92.7 lakhs while the company reported a net loss (around Rs.49.8 lakhs), accumulated losses exceed paid‑up capital, current liabilities outstrip current assets, and operating cash flow was a negative Rs.145.8 lakhs, signaling liquidity and going‑concern pressures. Management has raised conditional capital via a preferential allotment of 34,00,000 convertible warrants at Rs.12.50 each, receiving Rs.1.06 crore upfront (25%); the balance Rs.3.18 crore remains payable on exercise and will materially affect future equity, leverage and funding for the Rs.447 lakh project if converted, reflecting active balance sheet management. Audit scrutiny is heightened: auditors issued a qualified opinion due to non‑availability of confirmations for trade receivables, trade payables and loans/advances, and management reversed previously recognized deferred tax assets of Rs.27.93 lakhs, underscoring control, disclosure and recoverability concerns which directly impact investor confidence and financial statement reliability. The new chemical project installs 140 tpa capacity for 2,6‑Dichloro Aniline and 250 tpa for Para Chloro Meta Cresol with total project cost of Rs.447 lakh; if commissioned and operated at scale, the facility could shift Hemo Organic Limited’s revenue mix to higher‑margin intermediates, though successful commercialization depends on regulatory, environmental and offtake execution.

Over the past 52 weeks, Hemo Organic Ltd has traded between a low of ₹8.40 and a high of ₹24.42. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Hemo Organic Ltd has a market capitalization of approximately 7.27. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Hemo Organic Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 7.27 Cr, Hemo Organic Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Hemo Organic Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Hemo Organic Ltd is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Names mentioned include HDFC Bank, ICICI Bank, Axis Bank, IDBI Bank, Central Bank of India, Punjab & Sind Bank, India Cements, Ixigo, and several smaller firms such as Rossari Biotech and Hemo Organic.

Hemo Organic allotted 34,00,000 fully paid-up equity shares after converting an equal number of convertible warrants.

The company said it will hold a board meeting on October 3, 2026 to consider raising funds through equity shares and or convertible securities.

Dharmendrabhai Becharbhai Jasani bought 1,11,341 equity shares through an on-market transaction on September 7, 2026.